Concerns That May Limit the Utility of Zuranolone

JAMA. 2024 Jan 9;331(2):105-106. doi: 10.1001/jama.2023.26103.
No abstract available

Plain language summary

This Viewpoint discusses the evidence base of the US Food and Drug Administration approval of zuranolone.

MeSH terms

  • Antidepressive Agents* / therapeutic use
  • Drug Approval*
  • Pregnanes
  • Pyrazoles
  • United States
  • United States Food and Drug Administration

Substances

  • Pregnanes
  • Pyrazoles
  • zuranolone
  • Antidepressive Agents